# Nektar Therapeutics: overview NKTR · Nasdaq · CIK 906709 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nktr.md) · [Financials](/companies/nktr/financials.md) · [Filings](/companies/nktr/filings.md) · [Insiders](/companies/nktr/insiders.md) Latest reported revenue: [$10.1m](/filings/0001193125-26-349805.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-349805). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [24.1](/filings/0001193125-25-270230.md) | [29.2 d](/filings/0001193125-26-104547.md) | [10.5](/filings/0001193125-26-212596.md) | [11.2](/filings/0001193125-26-349805.md) | [11.8](/filings/0001193125-25-270230.md) | [21.8 d](/filings/0001193125-26-104547.md) | [10.9](/filings/0001193125-26-212596.md) | [10.1](/filings/0001193125-26-349805.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(142.4%)](/filings/0001193125-25-270230.md) | [49.2% d](/filings/0001193125-26-104547.md) | [(425.8%)](/filings/0001193125-26-212596.md) | [(324.2%)](/filings/0001193125-26-349805.md) | [(268.6%)](/filings/0001193125-25-270230.md) | [(126.9%) d](/filings/0001193125-26-104547.md) | [(359.6%)](/filings/0001193125-26-212596.md) | [(417.9%)](/filings/0001193125-26-349805.md) | | Net margin | % | [(153.6%)](/filings/0001193125-25-270230.md) | [24.9% d](/filings/0001193125-26-104547.md) | [(486.4%)](/filings/0001193125-26-212596.md) | [(372.2%)](/filings/0001193125-26-349805.md) | [(301.3%)](/filings/0001193125-25-270230.md) | [(165.4%) d](/filings/0001193125-26-104547.md) | [(413.4%)](/filings/0001193125-26-212596.md) | [(401.0%)](/filings/0001193125-26-349805.md) | | Diluted EPS | $ per share | [(2.66)](/filings/0001193125-25-270230.md) | not reported | [(3.62)](/filings/0001193125-26-212596.md) | [(2.95)](/filings/0001193125-26-349805.md) | [(1.87)](/filings/0001193125-25-270230.md) | not reported | [(1.82)](/filings/0001193125-26-212596.md) | [(1.23)](/filings/0001193125-26-349805.md) | | Free cash flow | $m | [(44.6) d](/filings/0001193125-25-270230.md) | [(46.6) d](/filings/0001193125-26-104547.md) | [(49.1)](/filings/0001193125-26-212596.md) | [(45.8) d](/filings/0001193125-26-349805.md) | [(48.9) d](/filings/0001193125-25-270230.md) | [(65.0) d](/filings/0001193125-26-104547.md) | [(44.3)](/filings/0001193125-26-212596.md) | [(75.9) d](/filings/0001193125-26-349805.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [102](/filings/0000950170-24-026249.md) | [92.1](/filings/0000950170-24-026249.md) | [90.1](/filings/0000950170-25-039389.md) | [98.4](/filings/0001193125-26-104547.md) | [55.2](/filings/0001193125-26-104547.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(437.8%)](/filings/0000950170-24-026249.md) | [(408.6%)](/filings/0000950170-24-026249.md) | [(292.6%)](/filings/0000950170-25-039389.md) | [(106.9%)](/filings/0001193125-26-104547.md) | [(253.7%)](/filings/0001193125-26-104547.md) | | Net margin | % | [(514.0%)](/filings/0000950170-24-026249.md) | [(400.0%)](/filings/0000950170-24-026249.md) | [(306.3%)](/filings/0000950170-25-039389.md) | [(120.9%)](/filings/0001193125-26-104547.md) | [(297.1%)](/filings/0001193125-26-104547.md) | | Diluted EPS | $ per share | [(2.86)](/filings/0000950170-24-026249.md) | [(1.97)](/filings/0000950170-24-026249.md) | [(1.45)](/filings/0000950170-25-039389.md) | [(8.68)](/filings/0001193125-26-104547.md) | [(9.73)](/filings/0001193125-26-104547.md) | | Free cash flow | $m | [(428)](/filings/0000950170-24-026249.md) | [(310)](/filings/0000950170-24-026249.md) | [(193)](/filings/0000950170-25-039389.md) | [(177)](/filings/0001193125-26-104547.md) | [(209)](/filings/0001193125-26-104547.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nktr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $353.8m | 5,067,920 | | Added +764,732 | | [Two Seas Capital LP](/funds/1823138.md) | 2026-06-30 | $215.9m | 3,092,234 | | Added +1,133,056 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $205.4m | 2,941,851 | | Added +2,249,201 | | [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $166.9m | 2,391,075 | | Reduced −168,520 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $104.5m | 1,496,849 | | Added +299,794 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $83.9m | 1,202,004 | | Added +271,263 | | [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $69.8m | 1,000,000 | | Added +715,000 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $65.4m | 936,560 | | Added +277,173 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $63.5m | 909,679 | | Added +664,952 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $61.5m | 881,306 | | Added +534,511 | ## Recent filings [All 1,352 filings](/companies/nktr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-01 | 11:57 ET | [8-K](/filings/0001213900-26-105453.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-105453 | | 2026-09-25 | 11:00 ET | [8-K](/filings/0001213900-26-103215.md) | 8.01 Other events | 0001213900-26-103215 | | 2026-09-08 | 20:10 ET | [8-K](/filings/0001213900-26-098042.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-098042 | | 2026-08-14 | 22:57 ET | [10-Q](/filings/0001193125-26-349805.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349805 | | 2026-08-13 | 20:25 ET | [8-K](/filings/0001213900-26-089137.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-089137 | | 2026-06-05 | 20:30 ET | [8-K](/filings/0001213900-26-065845.md) | 5.07 Shareholder vote results | 0001213900-26-065845 | | 2026-05-08 | 21:11 ET | [8-K](/filings/0001193125-26-214976.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-214976 | | 2026-05-08 | 22:20 ET | [10-Q](/filings/0001193125-26-212596.md) | Quarterly report, period 2026-03-31 | 0001193125-26-212596 | | 2026-05-07 | 20:30 ET | [8-K](/filings/0001213900-26-053369.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-053369 | | 2026-04-24 | 20:15 ET | [DEF 14A](/filings/0001140361-26-016708.md) | Proxy statement, period 2026-06-04 | 0001140361-26-016708 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-104547.md), filed Mar 13, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/3e5d9877-6a7e-4b66-8a14-3684fe273d5b) ## About the filer - CIK: 906709 - Tickers: NKTR - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.